Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

Arthritis and Rheumatism

Volumn 43, Issue 1, 2000, Pages 175-183

  Badger, Alison M ^a   Griswold, Don E ^a   Kapadia, Rasesh ^a   Blake, Simon ^a   Swift, Barbara A ^a   Hoffman, Sandy J ^a   Stroup, George B ^a   Webb, Edward ^a   Rieman, David J ^a   Gowen, Maxine ^a   Boehm, Jeffrey C ^a   Adams, Jerry L ^a   Lee, John C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INDOMETACIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SB 242235; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HISTOPATHOLOGY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PAW EDEMA; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHROGRAPHY; BONE DENSITY; DENSITOMETRY, X-RAY; EXTREMITIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMIDAZOLES; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MAGNETIC RESONANCE IMAGING; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RATS, INBRED LEW; TARSUS, ANIMAL; TIBIA; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034121690     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO;2-S     Document Type: Article

References (37)

1. Lee JC, Badger AM, Griswold DE, Dunnington D, Truneh A, Votta B, et al. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann N Y Acad Sci 1993;696:149-70.
2. Griswold DE, Hillegass LM, Meunier PC, DiMartino MJ, Hanna N. Effect of inhibitors of eicosanoid metabolism in murine collagen-induced arthritis. Arthritis Rheum 1988;31:1406-12.
3. Marshall PJ, Griswold DW, Breton J, Webb EF, Hillegass LM, Sarau HM, et al. Pharmacology of the pyrroloimidazole, SK&F 105809. Biochem Pharmacol 1991;42:313-24.
4. Griswold DE, Hillegass LM, Breton JJ, Esser KM, Adams JL. In vivo differentiation of classical non-steroidal antiinflammatory drugs (NSAID) from cytokine suppressive antiinflammatory drugs (CSAID) and other pharmacological classes using mouse tumor necrosis factor alpha (TNFα) production. Drugs Clin Res XIX 1993;6:243-8.
5. Boehm JC, Smietana JM, Sorenson ME, Garigipati RS, Gallagher TF, Sheldrake PL, et al. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J Med Chem 1993;39: 3929-37.
6. Dinarello CA. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol 1991;3:941-8.
7. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33: 305-15.
8. Dayer JM, Demczuk S. Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol 1984;7:387-413.
9. Cochran FC, Selph J, Sherman P. Insights into the role of nitric oxide in inflammatory arthritis. Med Res Rev 1966;16:547-63.
10. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 4th ed. Philadelphia: WB Saunders; 1993. p. 248-68.
11. Roodman GD. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993;53:S94-8.
12. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
13. Gallagher TF, Fier-Thompson SM, Garigipati RS, Sorenson ME, Smietana JM, Lee D, et al. 2,4,5-triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg Med Chem Lett 1995;5:1171-6.
14. Elliott MJ, Maini RN. New directions for biological therapy in rheumatoid arthritis. Int Arch Allergy Immunol 1994;104:112-5.
15. Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997;40:397-409.
16. Han J, Lee JD, Bibb SL, Ulevitch RJ. A MAP kinase targeted by endotoxin and in mammalian cells. Science 1994;265:808-11.
17. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, et al. Identification of a novel protein kinase cascade stimulated by chemical stress and heat shock which activates MAP kinase-activated protein MAPKAP kinase-2 and induces phosphorylation of the small heat shock proteins. Cell 1994;78: 1027-37.
18. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994; 78:1039-49.
19. Lee JC, Young PR. Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol 1996; 59:152-7.
20. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996;279:1453-61.
21. Reddy MP, Webb EF, Cassatt D, Maley D, Lee JC, Griswold DE, et al. Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses. Int J Immunopharmacol 1994;16:795-804.
22. Badger AM, Olivera D, Talmadge JE, Hanna N. Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action. Circ Shock 1989;27:51-61.
23. Olivera DL, Esser KM, Lee JC, Greig RG, Badger AM. Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock. Circ Shock 1992;37:301-6.
24. Badger AM, Cook MN, Lark MW, Newman-Tarr TM, Swift BA, Nelson AH, et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998;161:467-73.
25. Lee JC, Kassis S, Kumar S, Badger A, Adams JL. p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 1999;82:389-97.
26. Young PR, McLaughlin MM, Jumar S, Kassis S, Doyle ML, McNulty D, et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997;272:12116-21.
27. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997;235:533-8.
28. De Laszlo SE, Visco D, Agarwal L, Chang L, Chin J, Croft G, et al. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett 1998;8:2689-94.
29. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. J Biol Chem 1998;273:28766-72.
30. Webb EF, Griswold DE. Microprocessor-assisted plethysmograph for the measurement of mouse paw volume. J Pharmacol Methods 1984;12:149-53.
31. Aarden LA, Lansdorp P, de Groot E. A growth factor for B-cell hybridomas produced by human monocytes. Lymphokines 1985; 10:175-85.
32. Houssiau FA, Devogelaer J-P, van Damme J, Nagant de Deuxchaisnes C, van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
33. Swaak AJG, Rooyen A, van Nieuwenhuis E, Aarden LA. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol 1988;17:469-74.
34. Hirano T, Matsuda T, Turner M. Excessive production of IL-6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-802.
35. Lee JC, Votta B, Dalton BJ, Griswold DE, Bender PE, Hanna N. Inhibition of human monocyte IL-1 production by SK&F 86002. Int J Immunother 1990;VI:1-12.
36. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-33.
37. Wang ZL, Canagarajah BJ, Boehm JC, Kassis S, Cobb MH, Young PR, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998;6:1117-28.